The Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee convened on May 21, 2025, to discuss significant updates regarding grant awards and research initiatives aimed at combating cancer in Texas. The meeting focused on the certification of award slates and the recommendations from the Program Integration Committee (PIC) for the fiscal year 2025.

During the meeting, Mr. Burgess confirmed that the applications under consideration adhered to CPRIT's administrative rules, ensuring compliance throughout the review process. The committee reviewed a total of 47 grant applications, requesting nearly $70 million, which were categorized under various grant mechanisms. Notably, this included two new Requests for Applications (RFAs) developed with input from the geographic diversity advisory committee, aimed at enhancing investigator-initiated research and supporting core facilities at eligible institutions.

Dr. Labeaux presented the academic research program update, highlighting that the recommended grants address eight key program priorities, including innovative research projects and recruitment efforts. Among the 19 core facility grants received, 11 were recommended for funding, with a particular emphasis on facilities that support multiple institutions across Texas. This year, four grants specifically focused on drug discovery, a critical area for CPRIT's mission.

The committee also reviewed high-impact, high-risk research awards, with 17 out of 96 applications recommended for funding. These grants encompass a broad spectrum of cancer research, including new therapies and diagnostic techniques. Additionally, the meeting included discussions on early clinical investigator awards, which provide essential support for early-stage researchers.

The meeting concluded with a commitment to advancing cancer research and prevention efforts in Texas, with the next steps involving the finalization of grant awards and continued support for innovative research initiatives. The CPRIT Oversight Committee remains focused on fostering a collaborative environment to enhance cancer research and improve outcomes for patients across the state.